BL
BLRX.US BioLineRx Ltd
- Market cap
- USD 6.47M
- P/E
- -
- P/B
- 0.50x
- ROE
- -82.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is BLRX.US undervalued?
Graham numberThe Graham number of BioLineRx Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BioLineRx Ltd fundamental analysis
No fundamental analysis for BioLineRx Ltd yet.
BioLineRx Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BioLineRx Ltd
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for th…
Full company profileBioLineRx Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BioLineRx Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.80M | 28.9M | 1.19M | 1.55M |
| Gross Profit | -482K | -481K | -451K | -940K | -934K | -702K | -654K | 1.11M | 19.7M | 430K | 1.08M |
| Operating Income | -16.5M | -25.2M | -25.6M | -28.1M | -22.9M | -24.8M | -29.2M | -49.7M | -20.4M | -10.4M | -13.3M |
| EBITDA | -16.0M | -24.8M | -21.9M | -22.7M | -27.6M | -25.4M | -22.1M | -57.1M | 3.92M | -225K | -11.6M |
| Net Income | -15.8M | -24.4M | -23.0M | -25.4M | -30.0M | -27.1M | -25.0M | -60.6M | -9.22M | -1.18M | -11.3M |
| EPS | -169 | -162 | -127 | -104 | -71 | -24 | -19 | -38 | -4.62 | -0.29 | -2.55 |
| Balance Sheet | |||||||||||
| Total Assets | 38.9M | 61.0M | 56.2M | 53.6M | 47.3M | 81.4M | 76.4M | 63.9M | 38.9M | 40.9M | 33.5M |
| Total Liabilities | 3.91M | 8.08M | 14.9M | 20.2M | 25.3M | 13.3M | 25.5M | 50.7M | 25.4M | 17.6M | 16.9M |
| Shareholders' Equity | 35.0M | 52.9M | 41.3M | 33.4M | 22.0M | 68.1M | 50.8M | 13.2M | 13.5M | 18.2M | 13.8M |
| Cash & Short-term Investments | 35.6M | 49.5M | 30.2M | 27.5M | 22.6M | 57.1M | 51.1M | 43.0M | 19.6M | 20.9M | 13.1M |
| Total Debt | 343K | 250K | 8.73M | 10.5M | 7.68M | 4.65M | 12.3M | 11.6M | 15.0M | 10.1M | 7.94M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -14.5M | -20.5M | -24.2M | -22.7M | -23.2M | -23.6M | -26.2M | -22.6M | -43.9M | -8.14M | -11.1M |
| Capital Expenditure | 55.0K | 4.24M | 10.2M | 73.0K | 97.0K | 97.0K | 316K | 297K | 54.0K | 25.2K | 24.0K |
| Free Cash Flow | -14.6M | -24.8M | -34.4M | -22.7M | -23.2M | -23.7M | -26.6M | -22.9M | -43.9M | -8.16M | -11.1M |
| Ratios | |||||||||||
| ROE | -45.2% | -46.1% | -55.6% | -76.2% | -136.3% | -39.7% | -49.1% | -458.4% | -68.5% | -6.5% | -82.2% |
| ROA | -40.7% | -39.9% | -40.8% | -47.5% | -63.5% | -33.2% | -32.7% | -94.8% | -23.7% | -2.9% | -33.8% |
| Net Profit Margin | - | - | - | - | - | - | - | -1,262.8% | -31.9% | -99.6% | -729.2% |
| Debt to Equity | 0.01x | 0.00x | 0.21x | 0.31x | 0.35x | 0.07x | 0.24x | 0.88x | 1.12x | 0.56x | 0.58x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
BioLineRx Ltd dividends
BioLineRx Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 1:40 on Jan 30, 2025.
Who owns BioLineRx Ltd
- Insiders 3.43%
- Institutions 1.80%
- Public & others 94.77%
- Shares outstanding 4.98M
- Free float 4.14M
Top funds holding BLRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 999.00 | 0.04% | 0.00% | Mar 2025 |
Top institutions holding BLRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Susquehanna International Group, LLP | 30.9K | 0.62% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 15.4K | 0.31% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 14.8K | 0.30% | 0.00% | Jun 2026 |
| Rhumbline Advisers | 2.48K | 0.05% | +5.31% | Jun 2026 |
| Wells Fargo & Co | 2.00K | 0.04% | +14.29% | Jun 2026 |
| BNP Paribas Arbitrage, SA | 500.00 | 0.01% | -72.22% | Jun 2026 |
| Banque Cantonale Vaudoise | 321.00 | 0.01% | 0.00% | Jun 2026 |
| UBS Group AG | 101.00 | 0.00% | -80.91% | Jun 2026 |
| Goss Wealth Management LLC | 82.00 | 0.00% | -23.36% | Jun 2026 |
| Advisor Group Holdings, Inc. | 26.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 10.00 | 0.00% | 0.00% | Jun 2026 |
| Danske Bank A/S. | 2.00 | 0.00% | 0.00% | Jun 2026 |
| Citigroup Inc | 1.00 | 0.00% | -99.94% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Rockefeller Capital Management L.P. | 0.00 | 0.00% | -100.00% | Jun 2026 |
| XTX Topco Ltd | 0.00 | 0.00% | -100.00% | Jun 2026 |
BioLineRx Ltd company profile
- Company name
- BioLineRx Ltd
- Ticker
- BLRX.US
- Exchange
- USA Stocks
- Listed since
- Jul 25, 2011
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 20
- Fiscal year end
- December
- Address
- Modi?in Technology Park, Hevel Modi'in, Israel, 7177871
- Phone
- 972 8 642 9100
- Website
- biolinerx.com
About BioLineRx Ltd
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
BioLineRx Ltd management
5- Mr. Philip A. Serlin CPA, M.B.A.Chief Executive Officer · born 1960
- Ms. Mali Zeevi CPAChief Financial Officer · born 1976
- Dr. Ella Sorani Ph.D.Chief Development Officer · born 1968
- Mr. John LaceyHead of Corporate Communications & Investor Relations
- Mr. Raziel FriedTreasurer & Budgetary Control Director